Lynovex

Lynovex® (NM001) is a first-in-class orphan drug candidate for cystic fibrosis.

CARE CF 1 oral Lynovex clinical trial data published

Posted 29-Dec-2020

72 One Novabiotics March 2019 Fullsize Grant Anderson

NovaBiotics are delighted to announce that our CARE CF 1 phase 2b clinical trial data for oral Lynovex in infectious pulmonary exacerbations of cystic fibrosis is published today in PLOS ONE. Our findings further support the potential of Lynovex® as game-changer in CF therapy.


Our Lynovex infographic summarises the properties of Lynovex and the PLOS ONE research article is available here PLOS CARE CF 1 Research article

Care Cf 1 Oral Lynovex Clinical Trial Data Published

Patients at the centre of rare disease therapy development

Three Posters on New Lynovex Preclinical and Clinical Data

Novabiotics To Present New Data On Their Novel Cystic Fibrosis Drugs At The European Cf Society’S Annual Conference

Novabiotics Presenting New Data At European Cystic Fibrosis Conference